These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25243521)

  • 1. Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade?
    Yasuda Y; Fujii Y; Yuasa T; Yamamoto S; Yonese J; Fukui I
    Int J Urol; 2015 Jan; 22(1):132-3. PubMed ID: 25243521
    [No Abstract]   [Full Text] [Related]  

  • 2. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
    Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B
    Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade.
    Kamada S; Sakamoto S; Ando K; Muroi A; Fuse M; Kawamura K; Imamoto T; Suzuki H; Nagata M; Nihei N; Akakura K; Ichikawa T
    J Urol; 2015 Nov; 194(5):1264-70. PubMed ID: 25861958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
    Hashimoto K; Masumori N; Hashimoto J; Takayanagi A; Fukuta F; Tsukamoto T
    Jpn J Clin Oncol; 2011 Mar; 41(3):405-10. PubMed ID: 20947624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    Perachino M; Cavalli V; Bravi F
    BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial Comment to Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade?
    Sakamoto S
    Int J Urol; 2015 Jan; 22(1):134. PubMed ID: 25351852
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer.
    Bertaglia V; Tucci M; Fiori C; Aroasio E; Poggio M; Buttigliero C; Grande S; Saini A; Porpiglia F; Berruti A
    Clin Genitourin Cancer; 2013 Sep; 11(3):325-330.e1. PubMed ID: 23531429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
    J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
    Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of testosterone in managing advanced prostate cancer.
    Rove KO; Debruyne FM; Djavan B; Gomella LG; Koul HK; Lucia MS; Petrylak DP; Shore ND; Stone NN; Crawford ED
    Urology; 2012 Oct; 80(4):754-62. PubMed ID: 22795376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
    Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
    Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy.
    Kimura T; Onozawa M; Miyazaki J; Matsuoka T; Joraku A; Kawai K; Nishiyama H; Hinotsu S; Akaza H
    Int J Urol; 2014 Jun; 21(6):578-83. PubMed ID: 24405474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.